FONT-SIZE Plus   Neg

MorphoSys And Novozymes Sign Long-Term Alliance On Slonomics Technology

MorphoSys AG (MPSYY.PK) and Novozymes A/S Thursday said they have signed a multi-year licensing and technology transfer agreement. The agreement provides Novozymes with a non-exclusive license to use MorphoSys's proprietary Slonomics technology to develop novel products within the industrial biotechnology sector.

Novozymes becomes the first industrial biotech company to have access to Slonomics technology. Financial details were not disclosed.

Slonomics technology, which comprises patented methods and know-how, advanced materials and robotic equipment, allows combination of building blocks in exactly the preferred order and composition. Researchers can thus create only the desired diversity among a set of enzyme variants, eliminating all the undesired combinations. In a typical scenario, Novozymes' researchers can reduce the number of variants made from millions to ten thousand.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Wal-Mart Stores, Inc. (WMT) Tuesday said nearly half of its orders since Thanksgiving have been placed on a mobile device, double compared to last year. Star Wars toys, 4K HDTVs 50-55", drones, Xbox One and PS4 video game bundles, iPad Minis and 14-ft. trampolines were among the categories that gained... Customers of Time Warner Cable in Midwest experienced outages that lasted around two hours on Monday evening, as Americans were busy making their last minute online purchases on Cyber Monday. In a very quiet move that would have gone unnoticed but for a scrutiny into the LinkedIn profile, Google has lapped up Robert Rose, former autopilot software engineering manager of Tesla, as part of the company's Google Robotics unit.
comments powered by Disqus
Follow RTT